온도 안정성 mRNA 바이알의 국제적인 백신 접종 참여 확대는 어떤 영향을 미치고 있나요?

세계적인 백신접종 참여 확대는 온도 안정성 mRNA 바이알 시장의 성장을 가속할 것으로 예측되며, 이러한 바이알은 복잡한 콜드체인 시스템에 의존하지 않고 보관, 운송 및 유통을 용이하게 합니다.

시장보고서

상품코드

1877925

세계의 온도 안정성 mRNA 바이알 시장 보고서(2025년)

Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Global Market Report 2025

발행일: On demand Report | 리서치사:

The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

샘플 요청 목록에 추가

세계의 온도 안정성 mRNA 바이알 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 17억 7,000만 달러에서 2025년에는 20억 1,000만 달러로 확대되고, CAGR 13.8%로 성장이 전망되고 있습니다. 지난 몇 년간의 성장은 콜드체인 물류에 대한 수요 증가, mRNA 백신의 보급 확대, 백신 보관에 대한 정부 자금 증가, 세계적인 백신 접종 프로그램의 확대, 감염증을 대상으로 한 임상시험의 급증 등이 요인으로 생각됩니다.

온도 안정성 mRNA 바이알 시장 규모는 앞으로 수년간 급속한 성장이 예상됩니다. 2029년까지 33억 3,000만 달러에 달하고, CAGR은 13.4%가 될 전망입니다. 예측 기간의 성장 요인으로는 온도 안정성 제제에 대한 수요 증가, 콜드체인 비용 절감에 대한 주목 증가, 종양학 분야에서 mRNA 요법 채용 확대, 세계적인 예방접종 이니셔티브의 확대, 바이오 의약품 연구개발(R&D)에 대한 투자 증가 등을 들 수 있습니다. 이 기간의 주요 동향으로는 제제 과학의 진보, 콜드체인 불필요한 배송을 가능하게 하는 기술 혁신, 동결건조 mRNA 바이알의 개발, 안정성 시험 방법의 고도화, 공급망 감시의 디지털화 등을 들 수 있습니다.

세계적인 백신접종에 대한 참여 확대는 온도 안정성 mRNA 바이알 시장의 성장을 가속할 것으로 예측됩니다. 백신은 특정 질병에 대한 방어를 구축하기 위해 신체의 면역계를 자극하고 공정한 접근과 유통을 확보하는 국제적인 제휴를 통해 세계적인 백신 접종의 대처가 확대되고 있습니다. 온도 안정성 mRNA 바이알은 복잡한 콜드체인 시스템에 의존하지 않고 보관, 운송 및 유통을 용이하게 함으로써 이러한 노력을 지원하고 보다 광범위한 접근성과 지속적인 예방접종 커버리지를 지원합니다. 예를 들어, 2025년 10월에는 개발도상국의 어린이들에게 백신을 제공하는 미국 거점의 국제기관 'Gavi'가 Gavi 지원대상 저소득국에서 DTP3 백신의 접종률이 2023년 80%에서 82%로 상승해 유행 전 수준에 가까웠다고 보고했습니다. 이와 같이 세계적인 백신접종 참여 확대가 온도 안정성 mRNA 바이알 수요를 뒷받침하고 있는 것입니다.

이 시장의 기업은 제조 효율성과 세계적인 접근성 향상을 위한 혁신에 주력하고 있습니다. 기술 이전 모델, 즉 전문 지식과 제조 기술의 공유를 통해 현지 생산을 가능하게 하는 수법이 채용되어 생산 능력의 확대와 백신의 보다 광범위한 유통을 도모하고 있습니다. 예를 들어 2024년 1월에는 독일 SCHOTT Pharma가 -80°C라는 극저온을 견딜 수 있는 'EVERIC' 동결용 바이알을 발매했습니다. 이것은 mRNA 백신이나 유전자 치료 제품에 적합한 설계로 강도를 최적화하여 파손 위험을 감소시켜, 중요한 의약품의 손실을 방지하고 가동 중지 시간을 최소화합니다.

자주 묻는 질문

온도 안정성 mRNA 바이알 시장 규모는 어떻게 변화하고 있나요?
- 2024년 17억 7,000만 달러에서 2025년에는 20억 1,000만 달러로 확대될 것으로 예상되며, CAGR은 13.8%로 전망됩니다. 2029년까지는 33억 3,000만 달러에 이를 것으로 보이며, 이 기간 동안 CAGR은 13.4%가 될 것으로 예상됩니다.
온도 안정성 mRNA 바이알 시장의 성장 요인은 무엇인가요?
- 성장 요인으로는 콜드체인 물류에 대한 수요 증가, mRNA 백신의 보급 확대, 백신 보관에 대한 정부 자금 증가, 세계적인 백신 접종 프로그램의 확대, 감염증을 대상으로 한 임상시험의 급증 등이 있습니다.
온도 안정성 mRNA 바이알의 기술 혁신은 어떤 방향으로 진행되고 있나요?
- 주요 동향으로는 제제 과학의 진보, 콜드체인 불필요한 배송을 가능하게 하는 기술 혁신, 동결건조 mRNA 바이알의 개발, 안정성 시험 방법의 고도화, 공급망 감시의 디지털화 등이 있습니다.
온도 안정성 mRNA 바이알 시장에서의 주요 기업은 어디인가요?
- Arcturus Therapeutics Holdings Inc., CureVac AG, Sanofi SA, Lonza Group AG, Gerresheimer AG 등이 주요 기업으로 활동하고 있습니다.
온도 안정성 mRNA 바이알의 국제적인 백신 접종 참여 확대는 어떤 영향을 미치고 있나요?
- 세계적인 백신접종 참여 확대는 온도 안정성 mRNA 바이알 시장의 성장을 가속할 것으로 예측되며, 이러한 바이알은 복잡한 콜드체인 시스템에 의존하지 않고 보관, 운송 및 유통을 용이하게 합니다.

세계의 온도 안정성 mRNA 바이알 시장 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 온도 안정성 mRNA 바이알 시장 : 성장률 분석
세계의 온도 안정성 mRNA 바이알 시장 실적 : 규모와 성장, 2019-2024년
세계의 온도 안정성 mRNA 바이알 시장 예측 : 규모와 성장, 2024-2029년, 2034F
세계의 온도 안정성 mRNA 바이알 : 총 시장 규모(TAM)

제6장 시장 세분화

세계의 온도 안정성 mRNA 바이알 시장 : 제품 유형별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
지질 나노입자 제형
폴리머계 제형
동결건조 mRNA 바이알
기타 제품 유형
세계의 온도 안정성 mRNA 바이알 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
직접 판매
리셀러
온라인 판매
기타 유통 채널
세계의 온도 안정성 mRNA 바이알 시장 : 용도별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
백신
치료제
연구
기타 용도
세계의 온도 안정성 mRNA 바이알 시장 : 최종 사용자별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
병원 및 진료소
연구기관
제약 및 바이오테크놀러지 기업
기타 최종 사용자
세계의 온도 안정성 mRNA 바이알 시장 : 지질 나노입자 제형 유형별 분석과 예측, 2019-2024년, 2024-2029F, 2034F
양이온성 지질 나노입자
이온화성 지질 나노입자
중성 지질 나노입자
세계의 온도 안정성 mRNA 바이알 시장 : 폴리머계 제형 유형별 분석과 예측, 2019-2024년, 2024-2029F, 2034F
폴리에틸렌글리콜계 제형
고분자 미셀
덴드리머계 제형
세계의 온도 안정성 mRNA 바이알 시장 : 동결 건조 mRNA 바이알 유형별 분석과 예측, 2019-2024년, 2024-2029F, 2034F
일회 투여 바이알
다회 투여 바이알
세계의 온도 안정성 mRNA 바이알 시장 : 기타 제품 유형별 분석과 예측, 2019-2024년, 2024-2029F, 2034F
펩티드계 제형
단백질 기반 제형
하이브리드 제형

제7장 지역별/국가별 분석

세계의 온도 안정성 mRNA 바이알 시장 :지역별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
세계의 온도 안정성 mRNA 바이알 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

온도 안정성 mRNA 바이알 시장 : 경쟁 구도
온도 안정성 mRNA 바이알 시장 : 기업 프로파일
- Arcturus Therapeutics Holdings Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- CureVac AG : 개요, 제품 및 서비스, 전략 및 재무 분석
- Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
- Lonza Group AG : 개요, 제품 및 서비스, 전략 및 재무 분석
- Gerresheimer AG : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

Stevanato Group
Schott AG
CSafe Global
Gennova Biopharmaceuticals Ltd.
TTP Group
Peli BioThermal LLC
SiO2 Materials Science
Shijiazhuang Xinfuda Medical Packaging
Vaxess Technologies
Ethris
Lyophilization Techniques
20Med Therapeutics BV
EnsiliTech
HDT Bio Corp.
Emervax

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

온도 안정성 mRNA 바이알 시장(2029년) : 새로운 기회를 제공하는 국가
온도 안정성 mRNA 바이알 시장(2029년) : 새로운 기회를 제공하는 부문
온도 안정성 mRNA 바이알 시장(2029년) : 성장 전략
- 시장 동향에 기초한 전략
- 경쟁 전략

제36장 부록

JHS 25.12.09

A temperature-stable messenger ribonucleic acid (mRNA) vial is a specially engineered container designed to preserve the stability and efficacy of mRNA formulations without the need for ultra-cold storage. By employing advanced stabilization technologies, these vials protect the delicate mRNA molecules from degradation at higher temperatures, facilitating easier handling, broader distribution, and more reliable use of mRNA-based products.

The primary types of temperature-stable mRNA vials include lipid nanoparticle formulations, polymer-based formulations, lyophilized mRNA vials, and other variants. Lipid nanoparticle formulations encapsulate and safeguard mRNA molecules, enabling efficient delivery into cells. These vials are distributed through direct sales, distributors, online channels, and other avenues. They are applied in vaccines, therapeutics, research, and related fields and are utilized by hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, among other end-users.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The temperature-stable messenger ribonucleic acid (mRNA) vial market research report is one of a series of new reports from The Business Research Company that provides temperature-stable messenger ribonucleic acid (mRNA) vial market statistics, including temperature-stable messenger ribonucleic acid (mRNA) vial industry global market size, regional shares, competitors with a temperature-stable messenger ribonucleic acid (mRNA) vial market share, detailed temperature-stable messenger ribonucleic acid (mRNA) vial market segments, market trends and opportunities, and any further data you may need to thrive in the temperature-stable messenger ribonucleic acid (mRNA) vial industry. This temperature-stable messenger ribonucleic acid (mRNA) vial market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The temperature-stable messenger ribonucleic acid (mRNA) vial market size has grown rapidly in recent years. It will grow from $1.77 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth during the historic period can be attributed to the rising demand for cold chain logistics, increased adoption of mRNA vaccines, growing government funding for vaccine storage, expansion of global vaccination programs, and the surge in clinical trials targeting infectious diseases.

The temperature-stable messenger ribonucleic acid (mRNA) vial market size is expected to see rapid growth in the next few years. It will grow to $3.33 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to the rising demand for temperature-stable formulations, increasing focus on reducing cold chain expenses, growing adoption of mRNA therapies in oncology, expansion of global immunization initiatives, and rising investments in biopharmaceutical research and development (R&D). Key trends during this period include advancements in formulation science, innovations enabling cold chain-free delivery, developments in lyophilized mRNA vials, enhanced stability testing methods, and the digitalization of supply chain monitoring.

The increasing participation in global vaccination is expected to drive the growth of the temperature-stable messenger ribonucleic acid (mRNA) vial market. Vaccines stimulate the body's immune system to build protection against specific diseases, and global vaccination efforts are expanding through international collaboration that ensures equitable access and distribution. Temperature-stable mRNA vials facilitate these efforts by allowing easier storage, transportation, and distribution without relying on complex cold chain systems, supporting wider accessibility and sustained immunization coverage. For example, in October 2025, Gavi, a US-based international organization providing vaccines to children in developing countries, reported that DTP3 vaccine coverage in Gavi-supported lower-income countries rose to 82%, up from 80% in 2023, approaching pre-pandemic levels. This growing participation in global vaccination is therefore fueling demand for temperature-stable mRNA vials.

Companies in this market are focusing on innovation to improve manufacturing efficiency and global accessibility. Technology transfer models, which involve sharing expertise and manufacturing techniques to enable local production, are being adopted to expand production capacity and distribute vaccines more broadly. For instance, in January 2024, Germany-based SCHOTT Pharma launched EVERIC freeze vials, capable of withstanding temperatures as low as -80°C, suitable for mRNA and gene therapy products. Their strength-optimized design reduces breakage risk, preventing loss of critical medications and minimizing downtime.

In February 2023, Netherlands-based 20Med Equipment Solutions partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance RNA and DNA vaccine technologies. The collaboration focuses on bio-responsive nanoparticle technology to eliminate the need for frozen storage of mRNA vaccines, enhancing global vaccine accessibility. CEPI, a Norway-based organization, supports innovations such as temperature-stable mRNA vials to improve vaccine storage, distribution, and reach worldwide.

Major players in the temperature-stable messenger ribonucleic acid (mrna) vial market are Arcturus Therapeutics Holdings Inc., CureVac AG, Sanofi S.A., Lonza Group AG, Gerresheimer AG, Stevanato Group, Schott AG, CSafe Global, Gennova Biopharmaceuticals Ltd., TTP Group, Peli BioThermal LLC, SiO2 Materials Science, Shijiazhuang Xinfuda Medical Packaging, Vaxess Technologies, Ethris, Lyophilization Techniques, 20Med Therapeutics BV, EnsiliTech, HDT Bio Corp., and Emervax.

North America was the largest region in the temperature-stable messenger ribonucleic acid (mRNA) vial market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in temperature-stable messenger ribonucleic acid (mRNA) vial report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the temperature-stable messenger ribonucleic acid (mRNA) vial market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The temperature-stable messenger ribonucleic acid (mRNA) vial consists of sales of stoppers, seals, caps, labels, and packaging materials. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on temperature-stable messenger ribonucleic acid (mrna) vial market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for temperature-stable messenger ribonucleic acid (mrna) vial ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The temperature-stable messenger ribonucleic acid (mrna) vial market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product Type: Lipid Nanoparticle Formulations; Polymer-Based Formulations; Lyophilized Messenger Ribonucleic Acid (mRNA) Vials; Others Product Types
2) By Distribution Channel: Direct Sales; Distributors; Online Sales; Others Distribution Channels
3) By Application: Vaccines; Therapeutics; Research; Others Applications
4) By End User: Hospitals And Clinics; Research Institutes; Pharmaceutical And Biotechnology Companies; Others End Users
Subsegments:
1) By Lipid Nanoparticle Formulations: Cationic Lipid Nanoparticles; Ionizable Lipid Nanoparticles; Neutral Lipid Nanoparticles
2) By Polymer-Based Formulations: Polyethylene Glycol-Based Formulations; Polymeric Micelles; Dendrimer-Based Formulations
3) By Lyophilized Messenger Ribonucleic Acid Vials: Single-Dose Vials; Multi-Dose Vials
4) By Others Product Types: Peptide-Based Formulations; Protein-Based Formulations; Hybrid Formulations
Companies Mentioned: Arcturus Therapeutics Holdings Inc.; CureVac AG; Sanofi S.A.; Lonza Group AG; Gerresheimer AG; Stevanato Group; Schott AG; CSafe Global; Gennova Biopharmaceuticals Ltd.; TTP Group; Peli BioThermal LLC; SiO2 Materials Science; Shijiazhuang Xinfuda Medical Packaging; Vaxess Technologies; Ethris; Lyophilization Techniques; 20Med Therapeutics BV; EnsiliTech; HDT Bio Corp.; Emervax.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

1. Executive Summary

2. Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Characteristics

3. Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Trends And Strategies

4. Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Growth Analysis And Strategic Analysis Framework

5.1. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Growth Rate Analysis
5.4. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Total Addressable Market (TAM)

6. Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Segmentation

6.1. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lipid Nanoparticle Formulations
Polymer-Based Formulations
Lyophilized Messenger Ribonucleic Acid (mRNA) Vials
Others Product Types
6.2. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Direct Sales
Distributors
Online Sales
Others Distribution Channels
6.3. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Vaccines
Therapeutics
Research
Others Applications
6.4. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Research Institutes
Pharmaceutical & Biotechnology Companies
Others End Users
6.5. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Sub-Segmentation Of Lipid Nanoparticle Formulations, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cationic Lipid Nanoparticles
Ionizable Lipid Nanoparticles
Neutral Lipid Nanoparticles
6.6. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Sub-Segmentation Of Polymer-Based Formulations, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Polyethylene Glycol-Based Formulations
Polymeric Micelles
Dendrimer-Based Formulations
6.7. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Sub-Segmentation Of Lyophilized Messenger Ribonucleic Acid Vials, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single-Dose Vials
Multi-Dose Vials
6.8. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Sub-Segmentation Of Others Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Peptide-Based Formulations
Protein-Based Formulations
Hybrid Formulations

7. Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Regional And Country Analysis

7.1. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

8.1. Asia-Pacific Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

9.1. China Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Overview
9.2. China Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

10.1. India Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

11.1. Japan Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Overview
11.2. Japan Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

12.1. Australia Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

13.1. Indonesia Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

14.1. South Korea Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Overview
14.2. South Korea Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

15.1. Western Europe Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Overview
15.2. Western Europe Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

16.1. UK Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

17.1. Germany Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

18.1. France Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

19.1. Italy Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

20.1. Spain Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

21.1. Eastern Europe Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Overview
21.2. Eastern Europe Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

22.1. Russia Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

23.1. North America Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Overview
23.2. North America Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

24.1. USA Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Overview
24.2. USA Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

25.1. Canada Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Overview
25.2. Canada Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

26.1. South America Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Overview
26.2. South America Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

27.1. Brazil Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

28.1. Middle East Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Overview
28.2. Middle East Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

29.1. Africa Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Overview
29.2. Africa Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Competitive Landscape And Company Profiles

30.1. Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Competitive Landscape
30.2. Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Company Profiles
- 30.2.1. Arcturus Therapeutics Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. CureVac AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Gerresheimer AG Overview, Products and Services, Strategy and Financial Analysis

31. Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Other Major And Innovative Companies

31.1. Stevanato Group
31.2. Schott AG
31.3. CSafe Global
31.4. Gennova Biopharmaceuticals Ltd.
31.5. TTP Group
31.6. Peli BioThermal LLC
31.7. SiO2 Materials Science
31.8. Shijiazhuang Xinfuda Medical Packaging
31.9. Vaxess Technologies
31.10. Ethris
31.11. Lyophilization Techniques
31.12. 20Med Therapeutics BV
31.13. EnsiliTech
31.14. HDT Bio Corp.
31.15. Emervax

32. Global Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

34. Recent Developments In The Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market

35. Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market High Potential Countries, Segments and Strategies

35.1 Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market In 2029 - Countries Offering Most New Opportunities
35.2 Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market In 2029 - Segments Offering Most New Opportunities
35.3 Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer